Epigenetic therapy in gastrointestinal cancer: The right combination

Therapeutic Advances in Gastroenterology

Volumn 9, Issue 4, 2016, Pages 560-579

  Abdelfatah, Eihab ^a   Kerner, Zachary ^a   Nanda, Nainika ^b,c   Ahuja, Nita ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CIMP; colorectal cancer; DNMT inhibitor; epigenetic therapy; gastrointestinal cancer; HDAC inhibitor chemosensitization; immune therapy; radiosensitization

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; ANTINEOPLASTIC AGENT; AZACITIDINE; CAPECITABINE; CISPLATIN; DNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GUADECITABINE; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; IRINOTECAN; MOCETINOSTAT; OXALIPLATIN; PACLITAXEL; PEMBROLIZUMAB; PLACEBO; REGORAFENIB; ROMIDEPSIN; SORAFENIB; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CELL LINE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CHEMOSENSITIZATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CPG ISLAND; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; DNA METHYLATION; DRUG APPROVAL; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; EPIGENETICS; ESOPHAGUS CANCER; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; IMMUNOMODULATION; MEDICAL DECISION MAKING; NEUTROPENIA; NONHUMAN; NUCLEAR REPROGRAMMING; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER;

EID: 84975076985     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X16644247     Document Type: Review

References (137)

1. Adam J., Odhav B., Bhoola K., (2003) Immune responses in cancer. Pharmacol Ther 99: 113-132.
2. Ahrens T., Timme S., Hoeppner J., Ostendorp J., Hembach S., Follo M., et al. (2015) Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and azacytidine. Epigenetics 10: 431-445.
3. Arney K., Fisher A., (2004) Epigenetic aspects of differentiation. J Cell Sci 117: 4355-4363.
4. Azad N., Zahnow C., Rudin C., Baylin S., (2013) The future of epigenetic therapy in solid tumours-lessons from the past. Nat Rev Clin Oncol 10: 256-266.
5. Bae J., Kim J., Cho N., Kim T., Kang G., (2013) Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer 109: 1004-1012.
6. Baylin S., Jones P., (2011) A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 11: 726-734.
7. Bélanger A., Tojcic J., Harvey M., Guillemette C., (2010) Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC Mol Biol 11: 9.
8. Bertino E., Otterson G., (2011) Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 20: 1151-1158.
9. Brahmer J., Reckamp K., Baas P., Crinò L., Eberhardt W., Poddubskaya E., et al. (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123-135.
10. Cecconi D., Donadelli M., Dalla Pozza E., Rinalducci S., Zolla L., Scupoli M., et al. (2009) Synergistic effect of trichostatin a and 5-Aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. Proteomics 9: 1952-1966.
11. Chang H., Rha S., Jeung H., Jung J., Kim T., Kwon H., et al. (2010) Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. J Cancer Res Clin Oncol 136: 1901-1913.
12. Chang M., Uozaki H., Chong J., Ushiku T., Sakuma K., Ishikawa S., et al. (2006) CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res 12: 2995-3002.
13. Cheng Y., Zhang C., Zhao J., Wang C., Xu Y., Han Z., et al. (2010) Correlation of CpG island methylator phenotype with poor prognosis in hepatocellular carcinoma. Exp Mol Pathol 88: 112-117.
14. Chiappinelli K., Strissel P., Desrichard A., Li H., Henke C., Akman B., et al. (2015) Inhibiting DNA methylation causes an interferon response in cancer via DSRNA including endogenous retroviruses. Cell 162: 974-986.
15. Coronel J., Cetina L., Pacheco I., Trejo-Becerril C., González-Fierro A., De La Cruz-Hernandez E., et al. (2011) A double-blind, placebo-controlled, randomized phase iii trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol 28: S540-546.
16. Crea F., Giovannetti E., Cortesi F., Mey V., Nannizzi S., Gallegos Ruiz M., et al. (2009) Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Mol Cancer Ther 8: 1964-1973.
17. Dawson M., Kouzarides T., (2012) Cancer epigenetics: from mechanism to therapy. Cell 150: 12-27.
18. Derissen E., Beijnen J., Schellens J., (2013) Concise drug review: azacitidine and decitabine. Oncologist 18: 619-624.
19. Dokmanovic M., Clarke C., Marks P., (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5: 981-989.
20. Dombret H., Seymour J., Butrym A., Wierzbowska A., Selleslag D., Jang J., et al. (2015) International phase III study of azacitidine versus conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126: 291-299.
21. Esteller M., (2011) Non-coding RNAs in human disease. Nat Rev Genet 12: 861-874.
22. Esteller M., Catasus L., Matias-Guiu X., Mutter G., Prat J., Baylin S., et al. (1999) HMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 155: 1767-1772.
23. Esteller M., Tortola S., Toyota M., Capella G., Peinado M., Baylin S., et al. (2000) Hypermethylation-associated inactivation of P14(ARF) is independent of P16(INK4a) methylation and P53 mutational status. Cancer Res 60: 129-133.
24. Farris A., Misdraji J., Srivastava A., Muzikansky A., Deshpande V., Lauwers G., et al. (2008) Sessile serrated adenoma: challenging discrimination from other serrated colonic polyps. Am J Surg Pathol 32: 30-35.
25. Fei P., El-Deiry W., (2003) P53 and radiation responses. Oncogene 22: 5774-5783.
26. Feinberg A., Ohlsson R., Henikoff S., (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33.
27. Feinberg A., Tycko B., (2004) The history of cancer epigenetics. Nat Rev Cancer 4: 143-153.
28. Fetterly G., Brady W., Levea C., Litwin A., Zagst P., Prey J., et al. (2009) A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (folfiri) in advanced upper gastrointestinal cancers (Agc). ASCO Meeting Abstracts 27: e15540.
29. Flatmark K., Nome R., Folkvord S., Bratland A., Rasmussen H., Ellefsen M., et al. (2006) Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat Oncol 1: 25.
30. Fleisher A., Esteller M., Tamura G., Rashid A., Stine O., Yin J., et al. (2001) Hypermethylation of the HMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene 20: 329-335.
31. Folkvord S., Ree A., Furre T., Halvorsen T., Flatmark K., (2009) Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Biol Phys 74: 546-552.
32. Fu T., Pappou E., Guzzetta A., Jeschke J., Kwak R., Dave P., et al. (2012) CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis. Clin Cancer Res 18: 4743-4752.
33. Gagnon J., Bernard O., Villeneuve L., Têtu B., Guillemette C., (2006) Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res 12: 1850-1858.
34. Glasspool R., Teodoridis J., Brown R., (2006) Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 94: 1087-1092.
35. Gnyszka A., Jastrzebski Z., Flis S., (2013) DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res 33: 2989-2996.
36. Goffin J., Eisenhauer E., (2002) DNA methyltransferase inhibitors-state of the art. Ann Oncol 13: 1699-1716.
37. Gravina G., Festuccia C., Marampon F., Popov V., Pestell R., Zani B., et al. (2010) Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer 9: 305.
38. Guo Y., Engelhardt M., Wider D., Abdelkarim M., Lubbert M., (2006) Effects of 5-Aza-2'-deoxycytidine on proliferation, differentiation and P15/INK4b regulation of human hematopoietic progenitor cells. Leukemia 20: 115-121.
39. Herman J., Baylin S., (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.
40. Højfeldt J., Agger K., Helin K., (2013) Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov 12: 917-930.
41. Hollevoet K., Mason-Osann E., Muller F., Pastan I., (2015) Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line. PLoS One 10: e0122462.
42. Hoshino I., Matsubara H., Akutsu Y., Nishimori T., Yoneyama Y., Murakami K., et al. (2008) Role of histone deacetylase inhibitor in adenovirus-mediated P53 gene therapy in esophageal cancer. Anticancer Res 28: 665-671.
43. Iacopetta B., Kawakami K., Watanabe T., (2008) Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol 13: 498-503.
44. Imperiale T., Ransohoff D., Itzkowitz S., Levin T., Lavin P., Lidgard G., et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370: 1287-1297.
45. Ishiguro M., Iida S., Uetake H., Morita S., Makino H., Kato K., et al. (2007) Effect of combined therapy with low-dose 5-Aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15. Ann Surg Oncol 14: 1752-1762.
46. Issa J., Garcia-Manero G., Giles F., Mannari R., Thomas D., Faderl S., et al. (2004) Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-Aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635-1640.
47. Jackson K., Soutto M., Peng D., Hu T., Marshal D., El-Rifai W., (2011) Epigenetic silencing of somatostatin in gastric cancer. Dig Dis Sci 56: 125-130.
48. Jones P., Baylin S., (2007) The epigenomics of cancer. Cell 128: 683-692.
49. Jones P., Taylor S., (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20: 85-93.
50. Jover R., Nguyen T., Pérez-Carbonell L., Zapater P., Payá A., Alenda C., et al. (2011) 5-fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 140: 1174-1181.
51. Juergens R., Wrangle J., Vendetti F., Murphy S., Zhao M., Coleman B., et al. (2011) Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 1: 598-607.
52. Juo Y., Gong X., Mishra A., Cui X., Baylin S., Azad N., et al. (2015) Epigenetic therapy for solid tumors: from bench science to clinical trials. Epigenomics 7: 215-235.
53. Juo Y, Johnston F., Zhang D., Juo H., Wang H., Pappou E., et al. (2014) Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol 25: 2314-2327.
54. Kaminskas E., Farrell A., Wang Y., Sridhara R., Pazdur R., (2005) FDA drug approval summary: azacitidine (5-azacytidine, vidaza) for injectable suspension. Oncologist 10: 176-182.
55. Kang G., Shim Y., Jung H., Kim W., Ro J., Rhyu M., (2001) CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 61: 2847-2851.
56. Kantarjian H., Issa J., Rosenfeld C., Bennett J., Albitar M., Dipersio J., et al. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106: 1794-1803.
57. Karahoca M., Momparler R., (2013) Pharmacokinetic and pharmacodynamic analysis of 5-Aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics 5: 3.
58. Kato K., Iida S., Uetake H., Takagi Y., Yamashita T., Inokuchi M., et al. (2008) Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int J Cancer 122: 603-608.
59. Kawakami K., Matsunoki A., Kaneko M., Saito K., Watanabe G., Minamoto T., (2011) Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. Cancer Sci 102: 166-174.
60. Khalil A., Guttman M., Huarte M., Garber M., Raj A., Rivea Morales D., et al. (2009) Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 106: 11667-11672.
61. Kim K., Skora A., Li Z., Liu Q., Tam A., Blosser R., et al. (2014) Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci USA 111: 11774-11779.
62. Le D., Uram J., Wang H., Bartlett B., Kemberling H., Eyring A., et al. (2015) Pd-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 372: 2509-2520.
63. Li H., Chiappinelli K., Guzzetta A., Easwaran H., Yen R., Vatapalli R., et al. (2014) Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5: 587-598.
64. Ling Y., Huang G., Fan L., Wei L., Zhu J., Liu Y., et al. (2011) CPG island methylator phenotype of cell-cycle regulators associated with tnm stage and poor prognosis in patients with oesophageal squamous cell carcinoma. J Clin Pathol 64: 246-251.
65. Lunyak V., Rosenfeld M., (2008) Epigenetic regulation of stem cell fate. Hum Mol Genet 17: R28-36.
66. Ma J., Zhao J., Lu J., Jiang Y., Yang H., Li P., et al. (2012) Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancer. Int J Mol Med 30: 1403-1409.
67. Maes T., Carceller E., Salas J., Ortega A., Buesa C., (2015) Advances in the development of histone lysine demethylase inhibitors. Curr Opin Pharmacol 23: 52-60.
68. Mann B., Johnson J., Cohen M., Justice R., Pazdur R., (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247-1252.
69. Marks P., (2010) Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 1799: 717-725.
70. Marks P., Xu W., (2009) Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107: 600-608.
71. Matei D., Fang F., Shen C., Schilder J., Arnold A., Zeng Y., et al. (2012) Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 72: 2197-2205.
72. Mazur P., Herner A., Mello S., Wirth M., Hausmann S., Sanchez-Rivera F., et al. (2015) Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med 21: 1163-1171.
73. Meidhof S., Brabletz S., Lehmann W., Preca B., Mock K., Ruh M., et al. (2015) ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med 7: 831-847.
74. Min B., Bae J., Lee E., Yu H., Kim Y., Chang D., et al. (2011) The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 11: 344.
75. Missiaglia E., Donadelli M., Palmieri M., Crnogorac-Jurcevic T., Scarpa A., Lemoine N., (2005) Growth delay of human pancreatic cancer cells by methylase inhibitor 5-Aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene 24: 199-211.
76. Miyaki Y., Suzuki K., Koizumi K., Kato T., Saito M., Kamiyama H., et al. (2012) Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer. Int J Oncol 40: 217-226.
77. Mohandas T., Sparkes R., Shapiro L., (1981) Reactivation of an inactive human X chromosome: evidence for X inactivation by DNA methylation. Science 211: 393-396.
78. Momparler R., (2005) Pharmacology of 5-Aza-2'-deoxycytidine (Decitabine). Semin Hematol 42: S9-16.
79. Momparler R., Ayoub J., (2001) Potential of 5-Aza-2'-deoxycytidine (decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 34: S111-115.
80. Morita S., Iida S., Kato K., Takagi Y., Uetake H., Sugihara K., (2006) The synergistic effect of 5-Aza-2'-deoxycytidine and 5-fluorouracil on drug-resistant tumors. Oncology 71: 437-445.
81. Muller S., Filippakopoulos P., Knapp S., (2011) Bromodomains as therapeutic targets. Expert Rev Mol Med 13: e29.
82. Muntean A., Hess J., (2009) Epigenetic dysregulation in cancer. Am J Pathol 175: 1353-1361.
83. Ogino S., Goel A., (2008) Molecular classification and correlates in colorectal cancer. J Mol Diagn 10: 13-27.
84. Oguejiofor K., Hall J., Mani N., Douglas C., Slevin N., Homer J., et al. (2013) The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma. Clin Oncol (R Coll Radiol) 25: 630-638.
85. Olsen E., Kim Y., Kuzel T., Pacheco T., Foss F., Parker S., et al. (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25: 3109-3115.
86. Overman M., Eng C., Kee B., Fogelman D., Shroff R., Fark C., et al. (2014) A phase I/II study of azacitidine and capecitabine/oxaliplatin (capox) in refractory cimp-high metastatic colorectal cancer. J Clin Oncol 32: 488.
87. Petrocca F., Lieberman J., (2011) Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol 29: 747-754.
88. Piekarz R., Frye R., Turner M., Wright J., Allen S., Kirschbaum M., et al. (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27: 5410-5417.
89. Pinto A., Attadia V., Fusco A., Ferrara F., Spada O., Di Fiore P., (1984) 5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64: 922-929.
90. Plumb J., Strathdee G., Sludden J., Kaye S., Brown R., (2000) Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the HMLH1 gene promoter. Cancer Res 60: 6039-6044.
91. Reddy M., Zhang E., Natarajan R., (2015) Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia 58: 443-455.
92. Ree A., Dueland S., Folkvord S., Hole K., Seierstad T., Johansen M., et al. (2010) Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the pelvic radiation and vorinostat (PRAVO) phase I study. Lancet Oncol 11: 459-464.
93. Robert C., Rassool F., (2012) HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res 116: 87-129.
94. Rudek M., Zhao M., He P., Hartke C., Gilbert J., Gore S., et al. (2005) Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 23: 3906-3911.
95. Saelen M., Ree A., Kristian A., Fleten K., Furre T., Hektoen H., et al. (2012) Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. Radiat Oncol 7: 165.
96. Saleem A., Dutta J., Malegaonkar D., Rasheed F., Rasheed Z., Rajendra R., et al. (2004) The topoisomerase I- and P53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor. Oncogene 23: 5293-5300.
97. Schrump D., Fischette M., Nguyen D., Zhao M., Li X., Kunst T., et al. (2006) Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12: 5777-5785.
98. Schuebel K., Chen W., Cope L., Glockner S., Suzuki H., Yi J., et al. (2007) Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 3: 1709-1723.
99. Sekeres M., Cutler C., (2014) How we treat higher-risk myelodysplastic syndromes. Blood 123: 829-836.
100. Shakya R., Gonda T., Quante M., Salas M., Kim S., Brooks J., et al. (2013) Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma. Cancer Res 73: 885-896.
101. Sharma P., Allison J., (2015) The future of immune checkpoint therapy. Science 348: 56-61.
102. Sharma S., Lee D., Li B., Quinlan M., Takahashi F., Maheswaran S., et al. (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-80.
103. Shen L., Catalano P., Benson A., O'Dwyer P., Hamilton S., Issa J., (2007) Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 13: 6093-6098.
104. Shi C., Washington K., (2012) Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine. Am J Clin Pathol 137: 847-859.
105. Shiovitz S., Bertagnolli M., Renfro L., Nam E., Foster N., Dzieciatkowski S., et al. (2014) CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology 147: 637-645.
106. Shoji M., Ninomiya I., Makino I., Kinoshita J., Nakamura K., Oyama K., et al. (2012) Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma. Int J Oncol 40: 2140-2146.
107. Snover D., Jass J., Fenoglio-Preiser C., Batts K., (2005) Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. Am J Clin Pathol 124: 380-391.
108. Sorm F., Vesely J., (1968) Effect of 5-Aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 15: 339-343.
109. Srivastava P., Paluch B., Matsuzaki J., James S., Collamat-Lai G., Karbach J., et al. (2014) Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk Res 38: 1332-1341.
110. Steele N., Finn P., Brown R., Plumb J., (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 100: 758-763.
111. Stewart D., Donehower R., Eisenhauer E., Wainman N., Shah A., Bonfils C., et al. (2003) A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase I inhibitor MG98 administered twice weekly. Ann Oncol 14: 766-774.
112. Tan W., Zhou W., Yu H., Luo H., Shen L., (2013) The DNA methyltransferase inhibitor zebularine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo. Biochem Biophys Res Commun 430: 250-255.
113. Topalian S., Hodi F., Brahmer J., Gettinger S., Smith D., Mcdermott D., et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
114. Toyota M., Ahuja N., Ohe-Toyota M., Herman J., Baylin S., Issa J., (1999a) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96: 8681-8686.
115. Toyota M., Ahuja N., Suzuki H., Itoh F., Ohe-Toyota M., Imai K., et al. (1999b) Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59: 5438-5442.
116. Tsai H., Li H., Van Neste L., Cai Y., Robert C., Rassool F., et al. (2012) Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21: 430-446.
117. Tumeh P., Harview C., Yearley J., Shintaku I., Taylor E., Robert L., et al. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568-571.
118. Turcan S., Rohle D., Goenka A., Walsh L., Fang F., Yilmaz E., et al. (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483: 479-483.
119. Ueki T., Toyota M., Sohn T., Yeo C., Issa J., Hruban R., et al. (2000) Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 60: 1835-1839.
120. Van Kampen J., Marijnissen-Van Zanten M., Simmer F., Van Der Graaf W., Ligtenberg M., Nagtegaal I., (2014) Epigenetic targeting in pancreatic cancer. Cancer Treat Rev 40: 656-664.
121. Van Rijnsoever M., Elsaleh H., Joseph D., Mccaul K., Iacopetta B., (2003) CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 9: 2898-2903.
122. Vatapalli R., Guzetta A., Fu T., Syed L., Kwak R., Ahuja N., (2014) Improving sensitivity to irinotecan using 5-azacytidine in colon cancer cell lines. J Surg Res 179: 251-252.
123. Wang J., Wang B., Chen X., Bi J., (2011a) The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis 32: 411-416.
124. Wang P., Dong Q., Zhang C., Kuan P., Liu Y., Jeck W., et al. (2013) Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 32: 3091-3100.
125. Wang Z., Rao D., Senzer N., Nemunaitis J., (2011b) RNA interference and cancer therapy. Pharm Res 28: 2983-2995.
126. Weisenberger D., Siegmund K., Campan M., Young J., Long T., Faasse M., et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787-793.
127. Weiser T., Guo Z., Ohnmacht G., Parkhurst M., Tong-On P., Marincola F., et al. (2001a) Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 24: 151-161.
128. Weiser T., Ohnmacht G., Guo Z., Fischette M., Chen G., Hong J., et al. (2001b) Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg 71: 295-301.
129. Wrangle J., Wang W., Koch A., Easwaran H., Mohammad H., Vendetti F., et al. (2013) Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4: 2067-2079.
130. Xu W., Parmigiani R., Marks P., (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552.
131. Yi J., Dhir M., Van Neste L., Downing S., Jeschke J., Glöckner S., et al. (2011) Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res 17: 1535-1545.
132. Yoshimi A., Kurokawa M., (2011) Key roles of histone methyltransferase and demethylase in leukemogenesis. J Cell Biochem 112: 415-424.
133. You J., Jones P., (2012) Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22: 9-20.
134. Zagni C., Chiacchio U., Rescifina A., (2013) Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment. Curr Med Chem 20: 167-185.
135. Zeller C., Dai W., Steele N., Siddiq A., Walley A., Wilhelm-Benartzi C., et al. (2012) Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 31: 4567-4576.
136. Zhou L., Cheng X., Connolly B., Dickman M., Hurd P., Hornby D., (2002) Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 321: 591-599.
137. Zouridis H., Deng N., Ivanova T., Zhu Y., Wong B., Huang D., et al. (2012) Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med 4: 156ra140.